Search research articles
Contact Us
Filters
Showing results (811-820 of 1,038) with videos related to
Page
of 104
Sort By:
The Journal of Allergy and Clinical Immunology. Global
|
October 10, 2022
Haploidentical CD3<sup>+</sup> TCR αβ/CD19<sup>+</sup>-depleted HSCT for MHC class II deficiency and persistent SARS-CoV-2 pneumonitis
Subramaniam Ramanathan, Liz Veramendi-Espinoza, Benjamin Shillitoe, et al.
JMIR Formative Research
|
June 16, 2023
Models of Gender Dysphoria Using Social Media Data for Use in Technology-Delivered Interventions: Machine Learning and Natural Language Processing Validation Study
Cory J Cascalheira, Ryan E Flinn, Yuxuan Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 28, 2019
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
Ian W Flinn, Richard van der Jagt, Brad Kahl, et al.
Health Security
|
August 21, 2024
Building Clinical Care Capacity for Patients With Special Pathogens in Advance of the Next Outbreak
Lauren Wiesner, Jade Flinn, Brooke Brewer, et al.
Blood Advances
|
August 30, 2024
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
Amitkumar Mehta, Leslie Popplewell, Graham P Collins, et al.
Early Intervention in Psychiatry
|
October 4, 2025
The 'Reducing Psychosis Risk by Targeting Trauma' Trial: Protocol of a Feasibility Randomised Controlled Trial of Trauma-Focused Cognitive Behavioural Therapy and Eye Movement Desensitisation and Reprocessing Therapy for People With At-Risk Mental States
Filippo Varese, Kim Cartwright, Amanda Larkin, et al.
Scientific Reports
|
September 28, 2023
Fibroblast growth factors induce hepatic tumorigenesis post radiofrequency ablation
Aurelia Markezana, Mor Paldor, Haixing Liao, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 13, 2010
Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium
John D Hainsworth, Ian W Flinn, David R Spigel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2015
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens
Ruben Niesvizky, Ian W Flinn, Robert Rifkin, et al.
Cancer Research Communications
|
March 16, 2023
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
Kristie A Blum, Jeffrey G Supko, Michael B Maris, et al.
Page
of 104
Search research articles
Search
Showing results (811-820 of 1,038) with videos related to
Sort By:
Page
of 104
The Journal of Allergy and Clinical Immunology. Global
|
October 10, 2022
Haploidentical CD3<sup>+</sup> TCR αβ/CD19<sup>+</sup>-depleted HSCT for MHC class II deficiency and persistent SARS-CoV-2 pneumonitis
Subramaniam Ramanathan, Liz Veramendi-Espinoza, Benjamin Shillitoe, et al.
JMIR Formative Research
|
June 16, 2023
Models of Gender Dysphoria Using Social Media Data for Use in Technology-Delivered Interventions: Machine Learning and Natural Language Processing Validation Study
Cory J Cascalheira, Ryan E Flinn, Yuxuan Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 28, 2019
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
Ian W Flinn, Richard van der Jagt, Brad Kahl, et al.
Health Security
|
August 21, 2024
Building Clinical Care Capacity for Patients With Special Pathogens in Advance of the Next Outbreak
Lauren Wiesner, Jade Flinn, Brooke Brewer, et al.
Blood Advances
|
August 30, 2024
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
Amitkumar Mehta, Leslie Popplewell, Graham P Collins, et al.
Early Intervention in Psychiatry
|
October 4, 2025
The 'Reducing Psychosis Risk by Targeting Trauma' Trial: Protocol of a Feasibility Randomised Controlled Trial of Trauma-Focused Cognitive Behavioural Therapy and Eye Movement Desensitisation and Reprocessing Therapy for People With At-Risk Mental States
Filippo Varese, Kim Cartwright, Amanda Larkin, et al.
Scientific Reports
|
September 28, 2023
Fibroblast growth factors induce hepatic tumorigenesis post radiofrequency ablation
Aurelia Markezana, Mor Paldor, Haixing Liao, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 13, 2010
Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium
John D Hainsworth, Ian W Flinn, David R Spigel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2015
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens
Ruben Niesvizky, Ian W Flinn, Robert Rifkin, et al.
Cancer Research Communications
|
March 16, 2023
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
Kristie A Blum, Jeffrey G Supko, Michael B Maris, et al.
Page
of 104